Mirek Fatyga, PhD, on NSCLC: New Data on Stereotactic Body Radiotherapy vs Conventionally Fractionated Radiotherapy

February 08, 2022 By The ASCO Post Staff

Mirek Fatyga, PhD, of Mayo Clinic Arizona, discusses his findings on overall survival in patients with locally advanced non–small cell lung cancer who are treated with stereotactic body radiotherapy or conventionally fractionated radiotherapy. He notes that a high dose of > 50 Gy to the right-superior portion of the heart likely affects its conduction system. A low dose of < 5 Gy to the inferior segments of the heart may also cause heart damage and toxicity through blood irradiation.

 

Related Content